Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis
ObjectivesTo identify subgroups of patients with lung cancer receiving chemotherapy based on the severity dimension of symptom experience, and to examine changes in membership between these subgroups over time.MethodsPatients who were scheduled to receive chemotherapy completed the Chinese version o...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.522407/full |
| _version_ | 1818342122444554240 |
|---|---|
| author | Nannan Li Lili Hou Shu Li |
| author_facet | Nannan Li Lili Hou Shu Li |
| author_sort | Nannan Li |
| collection | DOAJ |
| description | ObjectivesTo identify subgroups of patients with lung cancer receiving chemotherapy based on the severity dimension of symptom experience, and to examine changes in membership between these subgroups over time.MethodsPatients who were scheduled to receive chemotherapy completed the Chinese version of the MD Anderson Symptom Inventory and the revised lung cancer module with a total of 19 symptom items. Data were collected at three time points: two weeks before chemotherapy (T1), after chemotherapy cycle 1 (T2), and after chemotherapy cycle 3 or above (T3). The latent profile analysis and latent transition analysis were used to identify underlying subgroups and describe changes in subgroup membership over time.ResultsFrom the total sample (N = 195), 160 patients completed the symptom assessment at T1, T2, and T3. Two distinct latent symptom profiles of patients could be identified at T1, T2, and T3, which were classified as “Mild” and “Moderate-Severe” profiles. From T1 to T2 and T3, members in the Mild profile were more likely to move to the Moderate-Severe profile. Chemotherapy protocols, prior surgery treatment, and level of education can predict the transitions.ConclusionResults provide a better understanding of the patient’s different symptom experiences and characteristics. These could help clinicians to anticipate symptom patterns and develop interventions in lung cancer patients who were scheduled to receive chemotherapy for the first time. |
| first_indexed | 2024-12-13T16:09:40Z |
| format | Article |
| id | doaj.art-c2e27a94a00a44f0ab70800388ac588b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T16:09:40Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-c2e27a94a00a44f0ab70800388ac588b2022-12-21T23:38:58ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.522407522407Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition AnalysisNannan Li0Lili Hou1Shu Li2School of Nursing, Shanghai Jiao Tong University, Shanghai, ChinaDepartment of Nursing, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaDepartment of Nursing, Shanghai Seventh People’s Hospital, Shanghai, ChinaObjectivesTo identify subgroups of patients with lung cancer receiving chemotherapy based on the severity dimension of symptom experience, and to examine changes in membership between these subgroups over time.MethodsPatients who were scheduled to receive chemotherapy completed the Chinese version of the MD Anderson Symptom Inventory and the revised lung cancer module with a total of 19 symptom items. Data were collected at three time points: two weeks before chemotherapy (T1), after chemotherapy cycle 1 (T2), and after chemotherapy cycle 3 or above (T3). The latent profile analysis and latent transition analysis were used to identify underlying subgroups and describe changes in subgroup membership over time.ResultsFrom the total sample (N = 195), 160 patients completed the symptom assessment at T1, T2, and T3. Two distinct latent symptom profiles of patients could be identified at T1, T2, and T3, which were classified as “Mild” and “Moderate-Severe” profiles. From T1 to T2 and T3, members in the Mild profile were more likely to move to the Moderate-Severe profile. Chemotherapy protocols, prior surgery treatment, and level of education can predict the transitions.ConclusionResults provide a better understanding of the patient’s different symptom experiences and characteristics. These could help clinicians to anticipate symptom patterns and develop interventions in lung cancer patients who were scheduled to receive chemotherapy for the first time.https://www.frontiersin.org/article/10.3389/fonc.2020.522407/fulllung cancer patientssymptom experiencechemotherapylatent transition analysissymptom profile |
| spellingShingle | Nannan Li Lili Hou Shu Li Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis Frontiers in Oncology lung cancer patients symptom experience chemotherapy latent transition analysis symptom profile |
| title | Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis |
| title_full | Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis |
| title_fullStr | Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis |
| title_full_unstemmed | Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis |
| title_short | Distinct Subgroups of Patients With Lung Cancer Receiving Chemotherapy: A Latent Transition Analysis |
| title_sort | distinct subgroups of patients with lung cancer receiving chemotherapy a latent transition analysis |
| topic | lung cancer patients symptom experience chemotherapy latent transition analysis symptom profile |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.522407/full |
| work_keys_str_mv | AT nannanli distinctsubgroupsofpatientswithlungcancerreceivingchemotherapyalatenttransitionanalysis AT lilihou distinctsubgroupsofpatientswithlungcancerreceivingchemotherapyalatenttransitionanalysis AT shuli distinctsubgroupsofpatientswithlungcancerreceivingchemotherapyalatenttransitionanalysis |